Published online: 2026-01-17

Results of a Randomized, Double-Masked, Placebo-Controlled Phase 1/2 Study of a TRPV1 antagonist SJP-0132 in Participants with Dry Eye Disease

Author(s): Tomoyuki Wada et al.

Source: American Journal of Ophthalmology
DOI: https://www.ajo.com/article/S0002-9394(26)00016-4/abstract